10-Q: Guardian Pharmacy Services Reports Strong Q3 2025 Growth

Guardian Pharmacy Services, Inc. reported a significant turnaround in profitability and robust revenue growth for the third quarter and first nine months of 2025, driven by organic expansion and strategic acquisitions.

Summary

• Net income attributable to Guardian Pharmacy Services, Inc. for Q3 2025 was $9.818 million, a substantial improvement from a loss of $121.990 million in Q3 2024.
• Year-to-date (YTD) net income attributable to Guardian Pharmacy Services, Inc. for September 30, 2025, was $28.296 million, compared to a loss of $121.990 million for the same period in 2024.
• Revenues for Q3 2025 increased by 20.0% to $377.427 million from $314.393 million in Q3 2024.
• YTD revenues for September 30, 2025, grew by 18.1% to $1,051.069 million from $889.840 million in the prior year.
• Organic growth contributed $43.0 million to the Q3 2025 revenue increase and $110.0 million to the YTD revenue increase.
• Acquisitions contributed $20.0 million to the Q3 2025 revenue increase and $51.2 million to the YTD revenue increase.
• Operating income for Q3 2025 was $16.354 million, a significant improvement from an operating loss of $104.613 million in Q3 2024.
• YTD operating income for September 30, 2025, was $41.939 million, compared to an operating loss of $79.675 million for the same period in 2024.
• Adjusted EBITDA for Q3 2025 increased to $27.275 million from $23.012 million in Q3 2024.
• YTD Adjusted EBITDA for September 30, 2025, increased to $75.659 million from $64.944 million in the prior year.
• Basic EPS for Q3 2025 was $0.16, up from $(2.00) in Q3 2024.
• YTD Basic EPS for September 30, 2025, was $0.46, up from $(2.00) in the prior year.
• Cash and cash equivalents stood at $36.487 million as of September 30, 2025, up from $4.660 million at December 31, 2024.
• Net cash provided by operating activities for the nine months ended September 30, 2025, was $65.655 million, an increase of $30.0 million from $35.623 million in the prior year.
• The company served approximately 204,000 residents in 8,200 LTCFs across 38 states as of September 30, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated a strong financial turnaround from significant losses to profitability, driven by robust revenue growth and improved operational efficiency. Strong cash flow from operations and reduced interest expense are also positive indicators. While there are ongoing acquisition-related costs and increased operating expenses due to growth, the overall trajectory is highly positive.

Positives

• Significant turnaround from net losses to substantial net income in both the quarter ($9.818 million) and year-to-date periods ($28.296 million).
• Strong revenue growth of 20.0% for Q3 2025 ($377.427 million) and 18.1% YTD ($1,051.069 million), driven by both organic expansion and strategic acquisitions.
• Operating income turned positive, reaching $16.354 million in Q3 2025 and $41.939 million YTD 2025, compared to significant losses in the prior year.
• Adjusted EBITDA showed healthy growth, increasing to $27.275 million in Q3 2025 and $75.659 million YTD 2025.
• Cash and cash equivalents increased significantly to $36.487 million as of September 30, 2025, from $4.660 million at December 31, 2024.
• Net cash provided by operating activities increased by $30.0 million to $65.655 million YTD 2025, indicating strong operational cash generation.
• Interest expense decreased substantially by 84.4% in Q3 and 82.4% YTD due to having no outstanding balances under the Credit Facility.
• The company expanded its resident base from 180,000 to 204,000 and prescriptions dispensed from 6.4 million to 7.3 million (Q3) and 18.4 million to 21.0 million (YTD).
• The Credit Facility maturity date was extended to April 23, 2027, and there are no outstanding borrowings under the line of credit as of September 30, 2025.

Negatives

• Cost of goods sold as a percentage of revenue slightly increased from 80.1% to 80.3% for the nine months ended September 30, 2025, compared to the prior year.
• Selling, general, and administrative expenses, while significantly lower due to reduced share-based compensation, increased by $10.9 million in Q3 and $23.6 million YTD due to increased employee headcount from organic growth and acquisitions.
• Net cash used in investing activities increased by $3.7 million to $27.515 million YTD 2025, primarily due to increased capital expenditures.
• Net cash used in financing activities for the nine months ended September 30, 2025, was $6.313 million, compared to $24.629 million provided in the prior year, reflecting the absence of IPO proceeds and ongoing payments.

Risks

• Ability to effectively execute business strategies, implement new initiatives, and improve efficiency.
• Ability to effectively market and sell, customer acceptance of, and competition for, pharmaceutical and health care services in new and existing markets.
• Relationships with pharmaceutical wholesalers and key manufacturers, long-term health care facilities (LTCFs), and health plan payors.
• Ability to maintain and expand relationships with LTCF operators on favorable terms.
• Impact of a national emergency, public health crisis, global pandemic, or outbreak of infectious disease on employees, business, supply chain, and the LTCFs served.
• Continuing government and private efforts to lower pharmaceutical costs, including by limiting pharmacy reimbursements.
• Changes in, and ability to comply with, healthcare and other applicable laws, regulations, or interpretations.
• Further consolidation of managed care organizations and other health plan payors and changes in the terms of agreements with these parties.
• Ability to retain members of the senior management team, local pharmacy management teams, and pharmacy professionals.
• Exposure to, and the results of, claims, legal proceedings, and governmental inquiries.
• Ability to maintain the security and integrity of operating and information technology systems and infrastructure (e.g., against cyber-attacks).
• Product liability, product recall, personal injury, or other health and safety issues related to the pharmaceuticals dispensed.
• Impact of supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals dispensed.
• Sufficiency of sources of liquidity and financial resources to fund future operating expenses and capital expenditure requirements, and the ability to raise additional capital, if needed.
• Misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals dispensed.
• Market price of Class A common stock has experienced, and may in the future experience, substantial volatility due to relatively lower trading volumes and a limited public float.

Future Outlook

We expect to acquire the minority membership interests of Non-Converted Subsidiaries after a period sufficient for them to adopt our operating practices and experience meaningful growth in residents served and earnings.

Management Comments

• Our disclosure controls and procedures were designed, and were effective, to provide assurance at a reasonable level that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management as appropriate to allow timely decisions regarding required disclosures.
• This report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
• The financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

Industry Context

We are a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. While our national competitors have primarily focused on skilled nursing facilities (SNNs), we believe we enjoy a strong competitive position as a large and purpose-built provider of pharmacy services to ALFs and BHFs. More than two-thirds of our annual revenue for each of the past three years has been generated from residents of ALFs and BHFs. LTCF industry trends, including aging demographics, increases in the number of assisted living residents, improving life expectancies and enhanced quality of care, have resulted in ALF and BHF resident populations that require assistance with their increasingly acute and complex healthcare needs.

Comparison to Industry Standards

• The company differentiates itself by primarily focusing on assisted living facilities (ALFs) and behavioral health facilities (BHFs), which it identifies as the most attractive and highest growth sector of the long-term care facility (LTCF) market. This contrasts with national competitors who have largely focused on skilled nursing facilities (SNFs).
• The filing does not provide specific comparable companies, projects, or results for direct quantitative assessment against industry benchmarks.

Corporate Governance

Legal Proceedings

• We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

Related Party Transactions

• The Corporate Reorganization involved the conversion of membership interests and Restricted Interest Unit awards into Common Units of Guardian Pharmacy, LLC, and then into Class B common stock, with a cash payment of $1.02 per share ($55.176 million total) to Class B common stockholders.
• The Q2 2025 Follow-On Offering involved certain selling shareholders, consisting of the company's founders (the Guardian Founders), selling 6,059,553 shares of Class A common stock, from which the company received no proceeds.
• Non-controlling interests exist in Non-Converted Subsidiaries, which the company expects to acquire over time.

Stakeholder Impact

• Shareholders: Significant increase in net income and EPS, automatic conversion of Class B to Class A common stock, potential for future volatility in Class A common stock price.
• Employees: Increased average employee headcount, share-based compensation awards (RSUs) under the 2025 LTIP.
• Customers (LTCFs and residents): Expansion of services to 204,000 residents in 8,200 LTCFs across 38 states, focus on high-touch, individualized clinical, drug dispensing, and administration capabilities.
• Suppliers (pharmaceutical wholesalers and manufacturers): Importance of relationships with these parties for business operations.
• Creditors (Regions Bank): Credit Facility maturity extended to April 23, 2027, with no outstanding principal under the Term Loan or line of credit as of September 30, 2025.

Next Steps

• Scheduled automatic conversion of 25% of Class B common stock to Class A common stock on March 28, 2026.
• Scheduled automatic conversion of 25% of Class B common stock to Class A common stock on September 27, 2026.
• Expectation to acquire minority membership interests of Non-Converted Subsidiaries after they adopt operating practices and achieve meaningful growth.
• Evaluation of the impact of new accounting standards (ASU 2023-09, 2024-03, 2025-03, 2025-04, 2025-05, 2025-06, 2025-07) for future annual and interim disclosures.

Key Dates

Recommendation

The company has demonstrated a remarkable financial turnaround, moving from significant losses to strong profitability in both the quarter and year-to-date periods. This is underpinned by robust revenue growth, driven by both successful organic expansion and strategic acquisitions. The substantial increase in operating income and Adjusted EBITDA, coupled with a healthy increase in cash from operations and a debt-free position on its credit facility, indicates strong operational execution and financial health. The focus on the high-growth ALF and BHF sectors, combined with a clear acquisition strategy for non-converted subsidiaries, positions the company for continued future growth. While some risks inherent to the healthcare industry exist, the current financial performance and strategic direction warrant a strong buy recommendation for long-term investors.

Keywords

Pharmacy services, Long-term care, LTCF, Assisted living, Behavioral health, ALF, BHF, Healthcare, Pharmaceuticals, SEC filing, 10-Q, Financial results, Acquisitions, Organic growth, IPO, GRDN